City Council formally moved forward with its 2026–2027 strategic plan process this week, approving a resolution to hold two public hearings before potential adoption in early April. The hearings are ...

-- CB-010 ANTLER 2L LBCL Phase 1 dataset expected to include at least six months of follow up on the majority of patients; ongoing interactions with FDA on potential pivotal trial design -- -- CB-011 ...

Prioritizing autoimmune programs aims to focus upon near-term and intermediate value creation potential, while retaining oncology programs as promising clinical data continues to mature - Company ...

MORRISTOWN, N.J.--(BUSINESS WIRE)--Majesco, a global leader in cloud insurance software solutions, today announced the release of its latest Thought Leadership report, Strategic Priorities 2025: A ...

Most companies think they’re agile because strategy moves quickly. The real test is how fast seller behavior follows and whether you can prove it in metrics that matter.

WASHINGTON, Feb. 18, 2026 /PRNewswire/ -- Reflecting an evolving insurance marketplace and risk landscape, the National Association of Insurance Commissioners' (NAIC) Members have adopted proactive ...

Forbes contributors publish independent expert analyses and insights. I write about self-leadership and leading others. Great strategy without disciplined execution is just wishful thinking. Most ...

– Strategic restructuring includes reduced operating expenses, delivering approximately $400 million in anticipated annual cost savings, and implementing a 36% workforce reduction of approximately 500 ...

One leader at Blue Shield California shares the company's strategic priorities. Dr. Pushwaz Virk serves as the Medical Director of Clinical Product Development, Care Innovation, and Technology ...

Cash, cash equivalents, and short-term investments of $113.1 million as of December 31, 2024, extend operational runway into the first quarter of 2026. Completion of enrollment in the ENERGY 3 pivotal ...

BOSTON, July 25, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and ...